Pharmaceuticals, Biotechnology and Life Sciences
ATLANTA–(BUSINESS WIRE)–Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today reported…
– Lonca BLA accepted by FDA with priority review; PDUFA date May 21, 2021
– Commercial, medical affairs, CMC and support functions prepared for potential Lonca approval
– Updated data for lead programs Lonca and Cami presented at American Society o…
Legend received approximately $659.8 million in gross proceeds through share capital increases during 2020, including a successful Nasdaq IPO with aggregate gross proceeds of $487.3 million.
U.S. FDA clearance for IND application for a Phase 1 clin…
SHANGHAI & PRINCETON, N.J.–(BUSINESS WIRE)–LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced the appointment of Yi Larson as Chief Financial Officer,…
– Lonca BLA accepted by FDA with priority review; PDUFA date May 21, 2021
– Commercial, medical affairs, CMC and support functions prepared for potential Lonca approval
– Updated data for lead programs Lonca and Cami presented at American Society o…
– The first two programs selected under the agreement are for oncology and CNS disorders –
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Boston Pharmaceuticals announced today a pioneering three-year out-license and option agreement with GlaxoSmithKline PLC (LSE…
Legend received approximately $659.8 million in gross proceeds through share capital increases during 2020, including a successful Nasdaq IPO with aggregate gross proceeds of $487.3 million.
U.S. FDA clearance for IND application for a Phase 1 clin…
100% kidney substrate reduction at 12 months post-gene therapy in the first patient dosed with the plato® gene therapy platform in FAB-GT1 trial for Fabry disease
One new patient dosed and three new patients enrolled in Fabry disease clinical trial …
– Lonca BLA accepted by FDA with priority review; PDUFA date May 21, 2021
– Commercial, medical affairs, CMC and support functions prepared for potential Lonca approval
– Updated data for lead programs Lonca and Cami presented at American Society o…
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three and 12 months ended December 31, 2020 after market close on Thursday, March 25, 2021 and will hold an inve…